Refractory or Relapsed Multiple Myeloma
1 competing product in clinical development for Refractory or Relapsed Multiple Myeloma.
Pipeline by Phase
Phase 31
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) | Celltrion | Phase 3 | Recruiting | 77 |